Search | Clinical Trials Finder

Conditions: Chronic Kidney Disease
Interventions: Gardasil® Vaccine (FDA-approved vaccination regimen); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 9 Years to 21 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Congenital Bleeding Disorder, Healthy
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Myotonic Dystrophy Type 1
Interventions: rhIGF-I/rhIGFBP-3, placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Orange, California • Sacramento, California • Kansas City, Kansas + 9 more

Conditions: Influenza Immunization, Health Volunteers
Interventions: Trivalent Recombinant Influenza Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Swiftwater, Pennsylvania

Conditions: Hairy Cell Leukemia
Interventions: Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: FluBlok®, Placebo; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 4,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 24
States / cities: Beverly Hills, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 9
States / cities: Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Interleukin-12, Paromomycin sulfate, Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV
Interventions: VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypoparathyroidism
Interventions: NPSP558; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 14
States / cities: Lakewood, California • Jacksonville, Florida • Chicago, Illinois + 11 more

Conditions: Anthrax
Interventions: PA83-FhCMB; Biological
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Hemophilia A
Interventions: PF-05280602; Biological
Lead sponsor: Catalyst Biosciences; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more

Conditions: HIV Infections
Interventions: CD4-IgG; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 5 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Chicago, Illinois + 4 more

Conditions: Pre-Eclampsia
Interventions: recombinant human relaxin; Drug
Lead sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Lexington, Kentucky • Cincinnati, Ohio

Conditions: Plasmodium Falciparum Malaria
Interventions: Malaria ICC-1132, Alhydrogel; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more

Conditions: Toxic Shock Syndrome Staphylococcal
Interventions: Aluminum hydroxide, STEBVax vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cerebral Hemorrhage
Interventions: Recombinant Tissue Plasminogen Activator (rt-PA); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neoplasms, Prostate Cancer, Lung Cancer, Breast Cancer, Colon Cancer
Interventions: ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral Mucin-1 (MUC1) vaccine, ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
Interventions: IMC-A12, mitotane; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Decatur, Illinois + 3 more

Conditions: Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3; Biological
Lead sponsor: Allertein Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Hemophilia A
Interventions: PLASMA DERIVED Factor VIII, Recombinant FVIII; Drug
Lead sponsor: Fondazione Angelo Bianchi Bonomi; Other
Eligibility: 1 Minute to 6 Years · Male only
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Progressive Multifocal Leukoencephalopathy
Interventions: NT-I7; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: Recombinant glycosylated human interleukin-7, Melphalan, Autologous hematopoietic cell transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

Treatment of Chronic Cryptosporidiosis in AIDS Patients

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

Evaluation of the Safety of Relaxin in Preeclampsia

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

Phase I STEBVax in Healthy Adults

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

Survey of Inhibitors in Plasma-Product Exposed Toddlers

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant